help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karpman, B. A.
Right arrow Articles by Fisher, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karpman, B. A.
Right arrow Articles by Fisher, D. A.

Journal of Clinical Endocrinology & Metabolism, Vol 64, 119-123, Copyright © 1987 by Endocrine Society

ARTICLES

Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate

BA Karpman, B Rapoport, S Filetti and DA Fisher

We describe the effect of administration of repeated doses of sodium ipodate in a newborn infant with hyperthyroidism due to transient Graves' disease. Pretreatment (day 3) serum T4 and T3 concentrations were 49 micrograms/dl and 590 ng/dl, respectively. With 24 h after the first dose of ipodate, serum T3 fell by 40%, and it subsequently ranged from 209-278 ng/dl throughout the 39-day ipodate treatment period. Serum T4 also decreased after ipodate administration to 69% and 41% of the pretreatment value after 72 h and 7 days of treatment, respectively; values thereafter during treatment ranged from 19-22 micrograms/dl. These plateau values are in the upper range of normal for the neonatal period. Rapid clinical improvement occurred as the hyperiodothyroninemia abated. Serum rT3 concentrations increased from 468-672 ng/dl to greater than 1400 ng/dl 24 h after each ipodate dose. Thyroid-stimulating immunoglobulin was present in maternal and cord sera, and the half-life of serum thyroid-stimulating immunoglobulin in the infant was approximately 12 days. Antithyroglobulin and antimicrosomal antibodies were present in the infant at 10 days of age, and the titers decreased progressively thereafter; the half-life for the antimicrosomal antibody titer was 3 weeks. The data suggest that sodium ipodate can be useful for treatment of neonatal hyperthyroidism due to Graves' disease.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. S. Dhillon, P. Cohan, D. F. Kelly, C. H. Darwin, K. V. Iyer, and I. J. Chopra
Treatment of Hyperthyroidism Associated with Thyrotropin-Secreting Pituitary Adenomas with Iopanoic Acid
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 708 - 711.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
A L Ogilvy-Stuart
Neonatal thyroid disorders
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2002; 87(3): F165 - 171.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Braga and D. S. Cooper
Oral Cholecystographic Agents and the Thyroid
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1853 - 1860.
[Abstract] [Full Text]

Home page
 NeoReviewsHome page
B. Buckingham
The Hyperthyroid Fetus and Infant
NeoReviews, June 1, 2000; 1(6): e103 - 109.
[Full Text]

Home page
 CLIN PEDIATRHome page
R. Joshi and H. E. Kulin
Treatment of Neonatal Graves' Disease with Sodium Ipodate: A Case Report
Clinical Pediatrics, March 1, 1993; 32(3): 181 - 184.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society